Can Semaglutide Be Taken Orally — and Does the Tablet Actually Work?

The biggest misconception: oral semaglutide is not new, but the weight-loss tablet is

A question our prescribers hear most weeks goes something like: "Can I just take the Ozempic pill instead of injecting?" It is an understandable leap, but it misses something important. Oral semaglutide for weight loss and oral semaglutide for type 2 diabetes are different licensed products with different dose strengths. Rybelsus (the diabetes tablet) comes in 3 mg, 7 mg and 14 mg doses and is not licensed or prescribed for weight management. Wegovy tablets, approved by the MHRA in June 2026, use a different strength ladder entirely: 1.5 mg, 4 mg, 9 mg and 25 mg. The two products share the active ingredient but serve different clinical purposes, and one cannot substitute for the other.

This distinction matters practically. If you have read about oral semaglutide online and found information about 3 mg or 14 mg doses, you have been reading about the diabetes product. For weight management, the escalation runs to 25 mg. Patients already established on the 2.4 mg weekly injection may, subject to clinical assessment, move directly to the 25 mg tablet rather than starting over at 1.5 mg, though that decision sits with a prescriber, not a self-switch. The Wegovy overview covers both the injection and tablet forms if you want to compare them side by side.

The NHS has not yet appraised the Wegovy tablet; a NICE appraisal would be required before NHS prescribing could begin. For now, it is available by private prescription only.

How an oral GLP-1 medicine works, and why the timing rules are strict

GLP-1 receptor agonists like semaglutide act on appetite-regulating pathways in the brain, slow gastric emptying and promote a sense of fullness after eating. The injection delivers the medicine directly under the skin, bypassing the digestive system. An oral GLP-1 faces a harder route: stomach acid and digestive enzymes break down peptide medicines quickly, and very little of a dose reaches the bloodstream without help.

The solution in Wegovy tablets is SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), an absorption enhancer that protects semaglutide as it crosses the stomach lining. Even so, absorption is finicky. The tablet must be taken on an empty stomach, first thing in the morning, with no more than about 120 ml of plain water, that is roughly half a standard mug. Food, coffee, other drinks or other oral medicines taken within 30 minutes blunt absorption significantly. That is not a suggested guideline; it is a pharmacological requirement baked into the product's licence.

For some people, the routine is easy: tablet before the kettle goes on, 30-minute gap, then breakfast as normal. Others find the morning window genuinely disruptive to existing medicines schedules. A prescriber reviewing your consultation will consider this alongside everything else. You can read more about how Wegovy is taken in practical terms, including what to do if the timing clashes with other morning medications.

What the evidence says about weight loss with the oral form

The phase 3 evidence for Wegovy tablets comes from the OASIS 4 trial: 307 adults with obesity or overweight and at least one weight-related condition, without diabetes, followed for 64 weeks. Participants taking semaglutide tablets lost an average of around 13.6% of body weight compared with approximately 2.4% on placebo, alongside lifestyle changes. Among those who adhered fully to treatment, average loss was around 16.6%. That fuller-adherence figure requires a specific framing: it reflects a subset, not the overall population average.

For context, the weekly 2.4 mg injection produced around 15% average loss in the STEP 1 trial at 68 weeks, as published in the New England Journal of Medicine. The injection at 7.2 mg moves closer to tirzepatide territory. The tablet's results sit modestly below the standard injection dose, which is a reasonable trade-off for people who strongly prefer not to inject. The right comparison is always individual, which is why the conversation starts with a prescriber rather than a comparison chart.

The most common side effects in the OASIS 4 trial were gastrointestinal: nausea, diarrhoea, constipation and indigestion. They followed the same pattern seen with the injection, more noticeable after starting or after a dose step up, generally easing over the following days to a couple of weeks. The semaglutide information page covers the side-effect profile in more detail, including which symptoms usually warrant contacting your prescriber.

Who the tablet might suit, and how to find out if it applies to you

The Wegovy tablet is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related health condition, the same broad eligibility as the injection. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI figures alone are not the whole picture; the prescriber's job is to assess whether the tablet is appropriate given your medical history, other medicines and morning routine.

The no-refrigeration requirement is a genuine practical advantage for people who travel frequently or who find keeping medication in the fridge disruptive. The strict morning-window requirement can cut the other way. Neither factor decides suitability on its own. If needles are the main reason you have held back from weight-management treatment, it is worth reading about whether taking semaglutide orally is suitable for you before deciding which route to pursue. The broader semaglutide options page sets out how the injection and tablet fit into the picture for different people.

For anyone weighing up treatment routes, a private consultation at a GPhC-registered pharmacy is the starting point. You can also explore what Wegovy treatment costs privately before committing to anything. If you are ready to find out whether oral semaglutide is a match for you, you can start a free consultation and have your answers reviewed the same day by a real clinician.